GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Bio-Physical Modeling of Immuno-Radiotherapy Combinations based on Patient Data

$216,282
Clemens Grassberger · Massachusetts General Hospital · R21 · FY2019 · CA

Liquid Biopsy Core

$216,213
Amir Goldkorn · University Of Southern California · P30 · FY2023 · CA

In situ single cell imaging

$216,126
Feng Gao · Dotquant, Llc · R44 · FY2019 · CA

Role of Acid in the Development of Barrett's Esophagus

$216,090
Rhonda F Souza · Ut Southwestern Medical Center · R01 · FY2008 · DK

Project 2: Chemotherapy-induced Immunomodulation in Colon Cancer

$216,070
Temesgen Samuel · Tuskegee University · U54 · FY2023 · CA

Project 2: Chemotherapy-induced Immunomodulation in Colon Cancer

$216,070
Temesgen Samuel · Tuskegee University · U54 · FY2022 · CA

Targeting USP10 to regulate the DNA damage response in NSCLC

$215,985
Xiaohong Mary Zhang · Wayne State University · R21 · FY2021 · CA

Exosome Signatures of Kidney Cancer Response to Immune Checkpoint Inhibitor

$215,985
Alice Chen Fan · Stanford University · R21 · FY2025 · CA

Quantitative evaluation of focused ultrasound thermal therapy on immunogenic cell death in breast cancer

$215,985
Allison Payne · Utah State Higher Education System--University Of Utah · R21 · FY2025 · CA

Liposome-based mRNA cancer immunotherapy targeting ion channels

$215,846
Laura Conforti · University Of Cincinnati · R21 · FY2024 · CA

Mitotic Catastrophe in Tumor Cells

$215,630
Ordway Research Institute, Inc. · R01 · FY2003 · CA

Mechanisms of resistance to immune therapy in NSCLC

$215,604
Qingsheng Li · University Of Louisville · P20 · FY2024 · GM

Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer

$215,495
Aadel Chaudhuri · Washington University · K08 · FY2020 · CA

Hormone Control of Cell Proliferation and Differentiation

$215,453
Virginia Rider · Pittsburg State University · · FY2001 · BIO

Bispecific drug-conjugates for treating colorectal cancer

$215,308
Kendra S. Carmon · University Of Texas Hlth Sci Ctr Houston · R21 · FY2025 · CA

CONTROL OF INITIATION OF DNA REPLICATION IN LUNG CANCER

$215,160
Edward M. Johnson · Eastern Virginia Medical School · R01 · FY2006 · CA

Investigating the Role of PFKFB4 in the Immune Regulation of Lung Cancer

$215,101
Sucheta Telang · University Of Louisville · R21 · FY2023 · CA

Cell-Free Nucleic Acids for Early Treatment Response Assessment of Hepatocellular Cancer

$214,949
Aadel Chaudhuri · Washington University · K08 · FY2021 · CA

Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer

$214,931
Samuel Lai · Univ Of North Carolina Chapel Hill · R21 · FY2023 · CA

Anti-tumor efficacy of novel cGAS-STING pathway agonists

$214,767
Victor Robert Defilippis · Oregon Health & Science University · R21 · FY2022 · CA

Mechanisms of Th17-DC immunotherapy for ovarian cancer

$214,583
Martin J Cannon · Univ Of Arkansas For Med Scis · R21 · FY2024 · CA

SR-A as a therapeutic target in breast cancer

$214,583
Post Steven · Univ Of Arkansas For Med Scis · R21 · FY2024 · CA

Development of pHLIP-phosphoantigen conjugates for lymphoma therapy

$214,513
Andrew J Wiemer · University Of Connecticut Storrs · R21 · FY2024 · CA

Understanding PD-L1/L2 protein regulation, detection and signaling to predict melanoma therapeutic sensitivity

$214,414
Roger S Lo · University Of California Los Angeles · R21 · FY2022 · CA

Structural Determinants in Cell Growth Control by p21 and p27

$214,402
Richard W Kriwacki · St. Jude Children'S Research Hospital · R01 · FY2008 · CA